 |
Crescendo Biologics
Last updated: January 21, 2024
Peter Pack, CEO
Country: UK | Funding: $148.2M (+)
Website: https://www.crescendobiologics.com/
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
Website: https://www.crescendobiologics.com/
Crescendo has developed a novel bispecific T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment
